Boehringer Ingelheim GmbH partnered with Newcastle University and the University of Edinburgh to fund a £30 million (US$38 million) study into liver cirrhosis in a bid to provide scientists with new insights into liver health. The partners hope that the study will not only enhance the understanding of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) cirrhosis, but also help identify translational biomarkers using a cutting-edge approach called single-cell RNA sequencing to accelerate the development of future therapies.
Veracyte Inc. revealed plans to buy C2i Genomics Inc. at the J.P. Morgan Health Care Conference in San Francisco on Jan. 8, a move that will significantly expand its portfolio of cancer diagnostic and monitoring assays. The terms include $70 million in Veracyte shares to be paid at closing plus an addition $25 million payable in cash or Veracyte shares over the next two years if C2i achieves certain performance milestones.
Keiferx LLC has expanded its exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities for the treatment of multiple disease indications.
Monte Rosa Therapeutics Inc. has described molecular glue degraders comprising cereblon ligands and a casein kinase 1 Isoform α (CK1α) targeting moiety acting as CK1α degradation inducers reported to be useful for the treatment of cancer.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are one of the major advances for non-small-cell lung cancer (NSCLC) management in recent years.
Olema Pharmaceuticals Inc. has advanced its program targeting KAT6, an epigenetic target dysregulated in breast and other cancers, with the selection of a development candidate, OP-3136. The orally bioavailable, potent KAT6A/B-selective inhibitor has been developed by Olema in collaboration with Aurigene Oncology Ltd.
RSS
